1. Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine Published: Apr 23, 2020 | Tags: Sanofi, Receives, US, FDA, Approval, MenQuadfi, Meningococcal, MenACWY, Conjugate Vaccine 2. Takeda to Divest Select OTC and Non-Core Assets in Europe to Orifarm for $670M Published: Apr 24, 2020 | Tags: Takeda, Divest, Select OTC and […]Read More
Tags : : RedHill Biopharma
COVID-19
Pharma
RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671)
Shots: RedHill in collaboration with NIAID will evaluate RHB-107 in non-clinical studies to determine its activity against SARS-CoV-2. The agreement will facilitate the pre-clinical evaluation of RHB-107 as a treatment for COVID-19 Additionally, RedHill is evaluating opaganib (Yeliva, ABC294640) against COVID-19. On Apr 17, the company unveils about the compassionate use of Opaganib is underway […]Read More
Shots: AstraZeneca to receive $52.5M up front and a non-contingent payment of $15M in 2021 while RedHill to get global rights of Movantik (Ex- EU, Canada and Israel). The divestiture allows AstraZeneca to focus on main therapy areas and is expected to be completed in Q1’20 AstraZeneca will transfer it 2015 co-commercialization agreement with Daiichi […]Read More
Shots: The approval is based on two P-III study results assessing Talicia vs active comparator arm and resulted in eradication of H. pylori infection (84% vs 58%), response rate @13 day (90.3% vs 64.7%), No resistance to rifabutin Talicia has market exclusivity of 8 years in the US under QIDP designation in addition to patent […]Read More
Latest Posts
